Unspecified

Extract from the above information

No specific pharmacological effects mentioned

The third generation of oral cephalosporins kill bacteria by inhibiting bacterial cell wall synthesis. They are stable to most β-lactamases and have good antibacterial effects on Gram-positive cocci such as pneumococci and Streptococcus pyogenes, and Gram-negative bacilli such as Haemophilus influenzae (including enzyme-producing strains), Moraxella catarrhalis (including enzyme-producing strains), Escherichia coli, Proteus mirabilis, and Neisseria gonorrhoeae (including enzyme-producing strains). In vitro, they also have antibacterial activity against Streptococcus pneumoniae, Parainfluenzae, Proteus vulgaris, Klebsiella pneumoniae, Pasteurella multocida, Providencia, Salmonella, Shigella, Serratia marcescens, Citrobacter heteromorphis, and Citrobacter malonate, but their clinical effectiveness has not yet been established. They have poor antibacterial effects on Staphylococcus, and have no antibacterial effects on Pseudomonas aeruginosa, Enterobacter, Bacteroides fragilis, and Clostridium.

This product is a second-generation cephalosporin antibiotic with a broad-spectrum antibacterial effect. Its bactericidal mechanism is to hinder the synthesis of bacterial cell walls.